|
US5919905A
(en)
*
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
|
USRE37582E1
(en)
|
1994-10-05 |
2002-03-12 |
Immunex Corporation |
Cytokine designated LERK-6
|
|
US20030228600A1
(en)
*
|
2000-07-14 |
2003-12-11 |
Eppendorf 5 Prime, Inc. |
DNA isolation method and kit
|
|
EP1474161A4
(en)
*
|
2002-01-16 |
2005-06-29 |
Zyomyx Inc |
BINDING PROGRAMS MANUFACTURED BY ENGINEERING
|
|
CA2486464A1
(en)
|
2002-05-21 |
2003-11-27 |
Resistentia Pharmaceuticals Ab |
Chimeric ige polypeptides and host cells
|
|
WO2004028551A1
(en)
|
2002-09-24 |
2004-04-08 |
The Burnham Institute |
Novel agents that modulate eph receptor activity
|
|
NZ544797A
(en)
|
2003-07-18 |
2011-04-29 |
Amgen Fremont Inc |
Specific antibodies that bind HGF and neutralise binding of HGF to met
|
|
EP1841790B1
(en)
|
2005-01-27 |
2010-11-03 |
The Burnham Institute |
Ephb receptor-binding peptides
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
US8314087B2
(en)
|
2007-02-16 |
2012-11-20 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and methods of use
|
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
|
TWI655210B
(zh)
*
|
2010-12-08 |
2019-04-01 |
艾伯維史坦森特瑞斯有限責任公司 |
新穎調節劑及其使用方法
|
|
DK2937349T3
(da)
|
2011-03-23 |
2017-02-20 |
Amgen Inc |
Kondenserede tricykliske dualinhibitorer af cdk 4/6 og flt3
|
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EP2890696A1
(en)
|
2012-08-29 |
2015-07-08 |
Amgen, Inc. |
Quinazolinone compounds and derivatives thereof
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
CA2923145C
(en)
|
2013-09-05 |
2025-09-16 |
Amgen Inc. |
MOLECULES CONTAINING FCS AND EXHIBITING PREDICTABLE, UNIFORM AND REPRODUCIBLE GLYCOFORM PROFILES
|
|
BR112016010051A2
(pt)
|
2013-11-04 |
2017-12-05 |
Pfizer |
?conjugados de anticorpo-fármaco anti-efna4?
|
|
MX377275B
(es)
|
2014-05-16 |
2025-03-07 |
Amgen Inc |
Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
|
|
EP3685819B1
(en)
*
|
2014-12-19 |
2023-11-01 |
L'oreal |
Solid anhydrous cosmetic composition, preparation process, cosmetic treatment processes and associated kit
|
|
AU2017229575A1
(en)
|
2016-03-08 |
2018-09-27 |
Janssen Biotech, Inc. |
GITR antibodies, methods, and uses
|
|
MX419976B
(es)
|
2016-07-14 |
2025-01-14 |
Scholar Rock Inc |
Anticuerpos de tgfb, métodos, y usos
|
|
CA3048217A1
(en)
|
2016-12-22 |
2018-06-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
AU2018235928B2
(en)
|
2017-03-14 |
2023-09-21 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
ES2905676T3
(es)
|
2017-05-22 |
2022-04-11 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos para su uso
|
|
CN111051306B
(zh)
|
2017-09-08 |
2023-01-03 |
美国安进公司 |
Kras g12c的抑制剂及其使用方法
|
|
CN119639849A
(zh)
|
2018-03-26 |
2025-03-18 |
美国安进公司 |
细胞培养物中产生的抗体的总去岩藻糖基化糖型
|
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
|
ES2995514T3
(en)
|
2018-05-04 |
2025-02-10 |
Amgen Inc |
Kras g12c inhibitors and methods of using the same
|
|
EP3790886B1
(en)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
CA3117222A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
|
WO2020132651A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
|
MX2021007157A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Heteroarilamidas utiles como inhibidores de kif18a.
|
|
PE20211475A1
(es)
|
2018-12-20 |
2021-08-05 |
Amgen Inc |
Inhibidores de kif18a
|
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
EP3930845A1
(en)
|
2019-03-01 |
2022-01-05 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
JP2022522777A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロアリール化合物及びその使用
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
CN114144414B
(zh)
|
2019-05-21 |
2025-11-07 |
美国安进公司 |
固态形式
|
|
WO2021026101A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
US12540129B2
(en)
|
2019-08-02 |
2026-02-03 |
Amgen Inc. |
KIF18A inhibitors
|
|
CN114302880B
(zh)
|
2019-08-02 |
2025-07-15 |
美国安进公司 |
Kif18a抑制剂
|
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
AU2020355251A1
(en)
|
2019-09-26 |
2022-04-21 |
Amgen Inc. |
Methods of producing antibody compositions
|
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
|
CA3158793A1
(en)
|
2019-10-28 |
2021-05-06 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
JP2023515235A
(ja)
|
2019-10-31 |
2023-04-12 |
大鵬薬品工業株式会社 |
４－アミノブタ－２－エンアミド誘導体及びその塩
|
|
CN114867735A
(zh)
|
2019-11-04 |
2022-08-05 |
锐新医药公司 |
Ras抑制剂
|
|
PE20221277A1
(es)
|
2019-11-04 |
2022-09-05 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN114786777A
(zh)
|
2019-11-04 |
2022-07-22 |
锐新医药公司 |
Ras抑制剂
|
|
PE20230249A1
(es)
|
2019-11-08 |
2023-02-07 |
Revolution Medicines Inc |
Compuestos de heteroarilo biciclicos y usos de estos
|
|
CA3158188A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
CA3163703A1
(en)
|
2020-01-07 |
2021-07-15 |
Steve Kelsey |
Shp2 inhibitor dosing and methods of treating cancer
|
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
WO2021247892A1
(en)
|
2020-06-04 |
2021-12-09 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
KR20230042600A
(ko)
|
2020-06-18 |
2023-03-28 |
레볼루션 메디슨즈, 인크. |
Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
|
|
JP7373664B2
(ja)
|
2020-07-15 |
2023-11-02 |
大鵬薬品工業株式会社 |
腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
|
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
AU2021345111B2
(en)
|
2020-09-15 |
2025-11-27 |
Revolution Medicines, Inc. |
Indole derivatives as Ras inhibitors in the treatment of cancer
|
|
AU2021360897A1
(en)
|
2020-10-15 |
2023-05-25 |
Amgen Inc. |
Relative unpaired glycans in antibody production methods
|
|
EP4267250A1
(en)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
CA3213636A1
(en)
|
2021-03-18 |
2022-09-22 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
|
AR125782A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
WO2022250170A1
(en)
|
2021-05-28 |
2022-12-01 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
|
AR126089A1
(es)
|
2021-06-07 |
2023-09-13 |
Amgen Inc |
Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
|
|
WO2023059607A1
(en)
|
2021-10-05 |
2023-04-13 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023064058A1
(en)
|
2021-10-12 |
2023-04-20 |
Peloton Therapeutics Inc. |
Tricyclic sultams and sulfamides as antitumor agents
|
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
IL314883A
(en)
|
2022-03-07 |
2024-10-01 |
Amgen Inc |
Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
AU2023285116A1
(en)
|
2022-06-10 |
2024-12-19 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
EP4601644A1
(en)
|
2022-10-14 |
2025-08-20 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
AU2024241633A1
(en)
|
2023-03-30 |
2025-11-06 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
EP4688790A1
(en)
|
2023-04-07 |
2026-02-11 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
WO2024216016A1
(en)
|
2023-04-14 |
2024-10-17 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024256160A1
(en)
|
2023-04-20 |
2025-10-02 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
CN121712509A
(zh)
|
2023-05-04 |
2026-03-20 |
锐新医药公司 |
用于ras相关疾病或病症的组合疗法
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
AU2024325342A1
(en)
|
2023-08-14 |
2026-02-26 |
Amgen Inc. |
Methods for reducing yellow color
|
|
WO2025043187A1
(en)
|
2023-08-24 |
2025-02-27 |
Otsuka Pharmaceutical Co., Ltd. |
Fixed dose combinations of cedazuridine and azacitidine
|
|
IL327306A
(en)
|
2023-10-12 |
2026-05-01 |
Revolution Medicines Inc |
Macrocyclic RAS inhibitors
|
|
WO2025085748A1
(en)
|
2023-10-20 |
2025-04-24 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of kras proteins
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
TW202602929A
(zh)
|
2024-03-21 |
2026-01-16 |
美商思進公司 |
Ｃｄ２５抗體、抗體-藥物共軛體及彼等之用途
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
WO2026090253A1
(en)
|
2024-10-23 |
2026-04-30 |
Amgen Inc. |
Methods of determining glycan pairing content
|